<DOC>
	<DOCNO>NCT01580670</DOCNO>
	<brief_summary>The purpose study evaluate efficacy TA-650 use Pediatric Crohn 's Disease Activity Index ( PCDAI ) evaluation indicator pediatric patient moderate severe Crohn 's disease TA-650 administration dose 5 mg/kg week 0 , 2 , 6 , every 8 week week 14 week 46 , dose 10 mg/kg effect attenuate . The safety pharmacokinetics also evaluate .</brief_summary>
	<brief_title>Clinical Study TA-650 Pediatric Patients With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Patients diagnose Crohn 's disease least 3 month prior screen . Have active Crohn 's disease despite adequate conventional therapy . Patients severe intestinal stricture ( stricture may affect number defecation , etc. , dilation colon strictures proximal small bowel observe barium radiograph , strictures preclude insertion endoscope ) , diagnosis short bowel syndrome , previous stoma surgery . Patients history treatment infliximab , biological product ( antiTNFÎ± agent antiIL6 agent , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Infliximab</keyword>
	<keyword>REMICADE</keyword>
	<keyword>TA-650</keyword>
	<keyword>pediatric Crohn 's disease</keyword>
</DOC>